Literature DB >> 17526734

Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.

Tamara Terzian1, Yongxing Wang, Carolyn S Van Pelt, Neil F Box, Elisabeth L Travis, Guillermina Lozano.   

Abstract

The tumor suppressor p53 is inactivated by multiple mechanisms that include mutations of the p53 gene itself and increased levels of the p53 inhibitors MDM2 and MDM4. Mice lacking Mdm2 or Mdm4 exhibit embryo-lethal phenotypes that are completely rescued by concomitant deletion of p53. Here we show that Mdm2 and Mdm4 haploinsufficiency leads to increased p53 activity, exhibited as increased sensitivity to DNA damage and decreased transformation potential. Moreover, in in vivo tumor development, Emu-myc Mdm4+/- mice show a delayed onset of B-cell lymphomas compared to Emu-myc mice. Additionally, Mdm2+/- Mdm4+/- double-heterozygous mice are not viable and exhibit defects in hematopoiesis and cerebellar development. The defects in Mdm2+/- Mdm4+/- mice are corrected by deletion of a single p53 allele. These findings highlight the exquisite sensitivity of p53 to Mdm2 and Mdm4 levels and suggest that some cell types may be more sensitive to therapeutic drugs that inhibit the Mdm-p53 interaction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17526734      PMCID: PMC1952101          DOI: 10.1128/MCB.00555-06

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  23 in total

1.  Achilles' heel of cancer?

Authors:  B Vogelstein; K W Kinzler
Journal:  Nature       Date:  2001-08-30       Impact factor: 49.962

2.  mdmx is a negative regulator of p53 activity in vivo.

Authors:  Rick A Finch; Dorit B Donoviel; David Potter; Min Shi; Amy Fan; Deon D Freed; Ching-Yun Wang; Brian P Zambrowicz; Ramiro Ramirez-Solis; Arthur T Sands; Nan Zhang
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

3.  Tumor suppression and normal aging in mice with constitutively high p53 activity.

Authors:  Susan M Mendrysa; Kathleen A O'Leary; Matthew K McElwee; Jennifer Michalowski; Robert N Eisenman; Douglas A Powell; Mary Ellen Perry
Journal:  Genes Dev       Date:  2006-01-01       Impact factor: 11.361

Review 4.  A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect.

Authors:  Gareth L Bond; Wenwei Hu; Arnold Levine
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

5.  Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.

Authors:  C M Eischen; J D Weber; M F Roussel; C J Sherr; J L Cleveland
Journal:  Genes Dev       Date:  1999-10-15       Impact factor: 11.361

6.  Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.

Authors:  J Parant; A Chavez-Reyes; N A Little; W Yan; V Reinke; A G Jochemsen; G Lozano
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

7.  An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2.

Authors:  S C Evans; M Viswanathan; J D Grier; M Narayana; A K El-Naggar; G Lozano
Journal:  Oncogene       Date:  2001-07-05       Impact factor: 9.867

8.  Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4.

Authors:  Jason D Grier; Shunbin Xiong; Ana C Elizondo-Fraire; John M Parant; Guillermina Lozano
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

9.  Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice.

Authors:  T J McDonnell; R Montes de Oca Luna; S Cho; L L Amelse; A Chavez-Reyes; G Lozano
Journal:  J Pathol       Date:  1999-07       Impact factor: 7.996

10.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.

Authors:  S N Jones; A E Roe; L A Donehower; A Bradley
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

View more
  72 in total

Review 1.  Mouse models of p53 functions.

Authors:  Guillermina Lozano
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

2.  MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress.

Authors:  Lynn Biderman; Masha V Poyurovsky; Yael Assia; James L Manley; Carol Prives
Journal:  Mol Cell Biol       Date:  2012-01-30       Impact factor: 4.272

3.  A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.

Authors:  Sean M Post; Alfonso Quintás-Cardama; Vinod Pant; Tomoo Iwakuma; Amir Hamir; James G Jackson; Daniela R Maccio; Gareth L Bond; David G Johnson; Arnold J Levine; Guillermina Lozano
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

4.  The ups and downs of p53 regulation in hematopoietic stem cells.

Authors:  Hussein A Abbas; Vinod Pant; Guillermina Lozano
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

Review 5.  Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.

Authors:  Zijun Y Xu-Monette; L Jeffrey Medeiros; Yong Li; Robert Z Orlowski; Michael Andreeff; Carlos E Bueso-Ramos; Timothy C Greiner; Timothy J McDonnell; Ken H Young
Journal:  Blood       Date:  2012-01-24       Impact factor: 22.113

6.  Tight regulation of p53 activity by Mdm2 is required for ureteric bud growth and branching.

Authors:  Sylvia Hilliard; Karam Aboudehen; Xiao Yao; Samir S El-Dahr
Journal:  Dev Biol       Date:  2011-03-21       Impact factor: 3.582

Review 7.  The p53 orchestra: Mdm2 and Mdmx set the tone.

Authors:  Mark Wade; Yunyuan V Wang; Geoffrey M Wahl
Journal:  Trends Cell Biol       Date:  2010-02-19       Impact factor: 20.808

8.  Guilty as CHARGED: p53's expanding role in disease.

Authors:  Jeanine L Van Nostrand; Laura D Attardi
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 9.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

Review 10.  p53--a Jack of all trades but master of none.

Authors:  Melissa R Junttila; Gerard I Evan
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.